Dan Hassett, PhD, in his laboratory at the University of Cincinnati
Arch Scientist Publishes Data on the Pre-Clinical Efficacy of AB569 in Killing of Drug Resistant Bacteria
21. Februar 2020 08:00 ET | Arch Biopartners
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9328b8b7-9f45-4361-915c-3a569b3716a0 TORONTO, Feb. 21, 2020 (GLOBE NEWSWIRE) --  Arch...
arch.png
Arch Biopartners Receives $332,750 From the Exercise of Warrants
26. Juni 2018 09:03 ET | Arch Biopartners
TORONTO, June 26, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners, Inc., (Arch or the Company) (TSX-V:ARCH) (OTCQB:ACHFF) a portfolio-based biotechnology company, today announced that it received net...
logo.png
Arch Biopartners Closes $1.25M Non-Brokered Private Placement Financing
09. März 2018 08:00 ET | Arch Biopartners
TORONTO, March 09, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture:ARCH) and (OTCBB:ACHFF), announced today it has closed the non-brokered private placement the...
logo.png
Arch Biopartners Closes Convertible Note Financing
16. Februar 2018 09:00 ET | Arch Biopartners
TORONTO, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX-V:ARCH) (OTCBB:ACHFF) announced it has closed the non-brokered, unsecured convertible note (“Note”)...
logo.png
Arch Biopartners Arranges Convertible Note Financing
08. Februar 2018 07:30 ET | Arch Biopartners
TORONTO, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture:ARCH) (OTCBB:ACHFF), announced it has arranged a non-brokered, unsecured convertible note...
logo.png
Arch Biopartners Announces Completion of GMP Manufacturing of AB569 and Start Date of Phase I Trial
06. Dezember 2017 10:08 ET | Arch Biopartners
TORONTO, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture:ARCH) (OTCBB:ACHFF) today announced that the good manufacturing practice (GMP) production...